Effect of route of administration and dose on diabetes-induced protection against cisplatin nephrotoxicity

Proceedings of the Society for Experimental Biology and Medicine

Volumn 212, Issue 4, 1996, Pages 362-368

  Sarangarajan, Rangaprasad ^a   Cacini, William ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NITROGEN; PLATINUM; STREPTOZOCIN; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHROTOXICITY; NONHUMAN; PROTECTION; RAT; STREPTOZOCIN DIABETES;

ANIMALIA;

EID: 0029796481     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-212-44027     Document Type: Article

References (14)

1. Vaamonde CA, Perez GO. Tubular function in diabetes mellitus. Sem Nephrol 10(3):203-218, 1990.
2. Teixeira RB, Kelly J, Alpert H, Pardo V, Vaamonde CA. Complete protection from gentamicin-induced acute renal failure in the diabetes mellitus rat. Kidney Int 21:600-612, 1982.
3. Scott LA, Madan E, Valentovic MA. Attenuation of cisplatin nephrotoxicity by streptozotocin-induced diabetes. Fund Appl Toxicol 12:530-539, 1989.
4. Ramsammy LS, Josepovitz C, Jones D, Ling KY, Lane BP, Kaloyanides GJ. Induction of nephrotoxicity by high doses of gentamicin in diabetic rats. Proc Soc Exp Biol Med 186:306-312, 1987.
5. Cacini W, Singh Y. Renal metallothionein and platinum levels in diabetic and non-diabetic rats injected with cisplatin. Proc Soc Exp Biol Med 197:285-289, 1991.
6. Cacini W, Harden EA, Skau KA. Reduced renal accumulation of cisplatin in experimental galactosemia. Proc Soc Exp Biol Med 203:348-353, 1993.
7. Ritschel WA. Handbook of Basic Pharmacokinetcs (4th ed). Hamilton, IL: Drug Intelligence Publications, pp291, 1992.
8. Ringler DH, Dabich L. Hematology and clinical biochemistry. In: Baker HJ, Lindsey JR, Weisbroth SH, Eds. The Laboratory Rat: Biology and Diseases. New York: Academic Press, p112, 1979.
9. Weiner MW, Jacobs C. Mechanisms of cisplatin nephrotoxicity. Fed Proc 42:2974-2978, 1983.
10. Borch RF. The Platinum Anti-Tumor Drugs. New York: Taylor and Francis Publishers, pp163, 1987.
11. Ward JM, Fauvie KA. The nephrotoxic effects of cis-damminedichloroplatinum (II) (NSC-119875) in male F344 rats. Toxicol Appl Pharmacol 38:535-547, 1976.
12. Goldstein R, Noordewier B, Bond JT, Hook JB, Mayor GH. Cis-dichlorodiammineplatinum nephrotoxicity: Time course and dose response of renal functional impairment. Toxicol Appl Pharmacol 60:163-175, 1981.
13. Goldstein RS, Mayor GH. The nephrotoxicity of cisplatin. Life Sci 32:685-690, 1983.
14. Rangaprasad S, Rathi S, Cacini W. Accumulation of cisplatin (CDDP) in renal cortex slices of non-diabetic and six week streptozotocin-diabetic (STZD) rats. FASEB J 9:A687, 1995.